Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney cancer of a specific type: clear cell or non-clear cell (not collecting duct type).
- Your primary kidney tumor is still present (no kidney removal yet).
- You have metastatic disease on recent imaging: CT of chest and CT/MRI of abdomen-pelvis done within the last 90 days (or per study timing).
- You must be able to safely undergo nephrectomy (kidney removal) with no clear reasons surgery is unsafe.
- You cannot have active brain metastases (past treated brain spots are allowed if you have no brain symptoms).
- After starting immunotherapy, scans about 12 weeks later must show stable disease/partial response or doctor-confirmed benefit (and you plan to keep the immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests whether giving two immunotherapy drugs before surgery can safely shrink kidney cancer tumors and help your body fight the cancer. You would receive the drugs before your scheduled surgery, and then your cancer would be removed as planned.
This trial tests whether the drug pembrolizumab, given after surgery to remove kidney cancer, can help prevent the cancer from coming back. Pembrolizumab helps your immune system fight cancer cells.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.